USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
GLYCOMIRA, LLC
Address:
675 ARAPEEN DR, STE 302
SALT LAKE CITY, UT 84108-
Phone:
N/A
URL:
N/A
EIN:
126289878
DUNS:
827444345
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $909,824.00 5
SBIR Phase II $1,500,000.00 1

Award List:

Sulfated Polysaccharide Derivatives for the Treatment of Rosacea

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$149,800.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Rosacea is a common disfiguring skin disease affecting 3% of the population over 30 years of age, or 14 million Americans. In men and women of Celtic origin, Rosacea causes central erythema of the face, with highly vis ible dilated blood vessels and pustules.… More

Sulfated Polysaccharide Derivatives for Treatment of Macular Degeneration

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$140,000.00
Agency:
HHS
Principal Investigator:
Jianxing Zhang
Abstract:
DESCRIPTION (provided by applicant): Age-related macular degeneration (AMD) is a leading cause of blindness in the U.S., affecting 8 million Americans over fifty years of age. Its cause is rooted in the highly oxidizing environment of the retina, which is simultaneously exposed to UV light and high… More

Novel Glycosaminoglycan Ethers for Prevention of Metastasis

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$210,000.00
Agency:
HHS
Principal Investigator:
Justin R. Savage – 801-649-3999
Abstract:
DESCRIPTION (provided by applicant): Heparin and its derivatives block P- and L-selectin mediated metastatic spread of cancer in animal models, and they potently inhibit the matrix degrading enzyme heparanase. Moreover, several large clinical trials performed with heparin or low molecular weight… More

Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$210,000.00
Agency:
HHS
Principal Investigator:
Justin R. Savage – 801-649-3999
Abstract:
DESCRIPTION (provided by applicant): Chronic gingival inflammation afflicts over half of all American adults and can progress to periodontal disease, eventually resulting in tooth loss. Periodontitis is initiated by bacterial infection of the gingival tissues through a subgingival microbial biofilm… More

Novel Glycosaminoglycan Derivatives for Treatment of Bladder Inflammation

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$200,024.00
Agency:
HHS
Principal Investigator:
Justin R. Savage – 801-649-3999
Abstract:
DESCRIPTION (provided by applicant): Painful bladder syndrome/interstitial cystitis (PBS/IC) is an indolent bladder disorder that has continued to be a debilitating disease with few truly effective treatment options. Inflammatory conditions that afflict the urinary bladder can lead to pelvic pain,… More

Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$1,500,000.00
Agency:
HHS
Principal Investigator:
Justin R. Savage – 801-649-3999
Abstract:
DESCRIPTION (provided by applicant): Chronic gingival inflammation of the soft tissue surrounding the tooth afflicts over half of all American adults. In the most severely affected, progression of this inflammatory process to the deeper periodontal ligaments and alveolar bone results in tooth loss… More